Astellas Pharma Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$50.1M
Doctors Paid
138
Transactions
5,948
2024 Total
$6.9M
Payment Breakdown by Category
Research$48.2M (96.2%)
Royalty/License$1.0M (2.0%)
Consulting$430,689 (0.9%)
Travel$385,982 (0.8%)
Food & Beverage$10,799 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $48.2M | 5,444 | 96.2% |
| Royalty or License | $1.0M | 44 | 2.0% |
| Consulting Fee | $430,689 | 144 | 0.9% |
| Travel and Lodging | $385,982 | 141 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $53,838 | 18 | 0.1% |
| Food and Beverage | $10,799 | 156 | 0.0% |
| Gift | $46.28 | 1 | 0.0% |
Payments by Type
Research
$48.2M
5,444 transactions
General
$1.9M
504 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation | $9.9M | 0 | 4,513 |
| PHASE I STUDY OF HU8F4 IN PATIENTS WITH ADVANCED HEMATOLGIC MALIGNANCIES | $6.5M | 0 | 1 |
| None | $6.0M | 2 | 7 |
| A Randomized, Double-blind, Placebo-controlled Adaptive Phase 2/3 Study With Open-label Extension to Assess the Efficacy, Safety and Tolerability of ASP0367 in Participants With Primary Mitochondrial Myopathy | $1.9M | 0 | 421 |
| Astellas-DFCI KRAS research collaboration | $1.8M | 0 | 1 |
| Immunotherapy Platform Research Preclinical Development of ASP9801 for Solid Tumor Liver Metastases | $1.0M | 0 | 1 |
| Astellas-DFCI Dr. Fischer research collaboration | $961,662 | 0 | 2 |
| Astellas-MGH Dr Xu Wu research collaboration | $867,530 | 0 | 1 |
| Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial | $857,205 | 0 | 1 |
| A Randomized, Double Blind, Placebo-Controlled Phase 1b Study With Open-Label Extension to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Patients With Duchenne Muscular Dystrophy (DMD) | $740,222 | 0 | 104 |
| GLP tox study | $681,813 | 0 | 1 |
| TEAD AUTOPALMITOYLATION COLLABORATION PROJECT | $500,000 | 0 | 1 |
| A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well | $487,415 | 3 | 64 |
| A Phase 1, Open-label Study to Evaluate the Absorption, Metabolism and Excretion of [14C]ASP0367 Solution in Healthy Male Participants | $401,895 | 0 | 5 |
| A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function | $383,995 | 0 | 24 |
| A Phase 1 Open-label Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP0367 Compared to Participants With Normal Hepatic Function | $363,434 | 0 | 24 |
| NOVEL PROTEIN DEGRADER PLATFORM IN THE FIELD OF ONCOLOGY | $360,693 | 0 | 1 |
| A Phase 1 Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Hepatic Function | $343,606 | 0 | 31 |
| Optimization of a Staphylococcus aureus MAPS vaccineTherapeutic Targets | $341,578 | 0 | 1 |
| A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function | $273,594 | 0 | 39 |
| A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People | $268,839 | 4 | 52 |
| COLLABORATION BETWEEN ASTELLAS AND IU FOR THE PRE-CLINICAL EVALUATION OF PD-1 AGONISTS ON TYPE 1 DIABETES PATHOGENESIS | $247,880 | 0 | 6 |
| A Phase 1 Open-label Study to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Gilteritinib Compared to Healthy Participants With Normal Renal Function | $213,816 | 0 | 18 |
| Astellas-Upenn ASP2215 collaboration | $176,342 | 0 | 1 |
| Targeting telomerase via non-coding RNA pathways in cancer | $175,611 | 0 | 1 |
| A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function | $173,418 | 0 | 29 |
| Using PrimaryFibroblasts and iPSC-Derived Neurons from Patients with AP-4-associatedHereditary Spastic Paraplegia to Support an Unbiased Autophagy-basedPhenotypic Screening for Novel Therapeutic Targets | $150,000 | 0 | 1 |
| Targeting the RNA methyltransferase METTL1 in cancer | $150,000 | 0 | 1 |
| A Phase 1 Open Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ASP0367 in Participants With Renal Impairment Compared to Healthy Participants With Normal Renal Function | $137,932 | 0 | 4 |
| Exploration of clinical biomarkers in multiple system atrophy | $134,776 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Shin Mineishi, Md, MD | Internal Medicine | Hershey, PA | $52,580 | $0 |
| William Oh, M.d, M.D | Medical Oncology | Greenwich, CT | $52,195 | $0 |
| Brian Lacy, Ph.d; M.d, PH.D; M.D | Gastroenterology | Lebanon, NH | $42,857 | $0 |
| Satish Rao, Md Phd, MD PHD | Internal Medicine | Augusta, GA | $42,503 | $0 |
| Dr. Stanley Jordan, Md, MD | Internal Medicine | West Hollywood, CA | $36,903 | $0 |
| Mark Levis, M.d, M.D | Internal Medicine | Baltimore, MD | $34,981 | $0 |
| Peter Odonnell | Internal Medicine | Chicago, IL | $33,960 | $0 |
| Christopher Evans, M.d, M.D | Urology | Reno, NV | $31,704 | $0 |
| Celestia Higano, Md, MD | Hematology & Oncology | Seattle, WA | $30,525 | $0 |
| Dr. Cornelius Clancy, Md, MD | Infectious Disease | Gainesville, FL | $24,911 | $0 |
| Dr. Peter Stock, Md, MD | Transplant Surgery | San Francisco, CA | $24,166 | $0 |
| Sandip Vasavada, Md, MD | Urology | Cleveland, OH | $21,158 | $0 |
| Dr. Terence Friedlander, Ms, MS | Hematology & Oncology | San Francisco, CA | $20,631 | $0 |
| Elizabeth Shpall, M.d, M.D | Medical Oncology | Houston, TX | $19,291 | $0 |
| Dr. John Kellum, Md, MD | Specialist | Pittsburgh, PA | $18,538 | $0 |
| James Markmann, Md, MD | Transplant Surgery | Philadelphia, PA | $16,906 | $0 |
| Roger Dmochowski, Md, MD | Urology | Nashville, TN | $16,849 | $0 |
| Christopher Sweeney, M.d, M.D | Medical Oncology | Boston, MA | $16,680 | $0 |
| Dr. Steven Balk | Hematology & Oncology | Boston, MA | $15,747 | $0 |
| Dr. Catherine Smith, M.d, M.D | Internal Medicine | San Francisco, CA | $15,433 | $0 |
| Hiroshi Miyamoto, M.d., Ph.d, M.D., PH.D | Anatomic Pathology | Rochester, NY | $15,120 | $0 |
| Alexander Perl, Md, MD | Medical Oncology | Philadelphia, PA | $13,587 | $0 |
| Nicholas Leeper, Md, MD | Cardiovascular Disease | Palo Alto, CA | $13,282 | $0 |
| Stephen Young, Md, MD | Cardiovascular Disease | Los Angeles, CA | $12,893 | $0 |
| Linda Cripe, M.d, M.D | Pediatric Cardiology | Columbus, OH | $12,760 | $0 |
Ad
Top Products
- Non-Marketed Product $10.6M
- XOSPATA $2.6M
Associated Products (2)
- Non-Marketed Product $10.6M
- TACROLIMUS CAPSULES $32,909
Payment Categories
- Food & Beverage $10,799
- Consulting $430,689
- Travel & Lodging $385,982
- Research $48.2M
- Royalties $1.0M
About Astellas Pharma Inc
Astellas Pharma Inc has made $50.1M in payments to 138 healthcare providers, recorded across 5,948 transactions in the CMS Open Payments database. In 2024, the company paid $6.9M. The top product by payment volume is Non-Marketed Product ($10.6M).
Payments were distributed across 40 medical specialties. The top specialty by payment amount is Internal Medicine ($236,208 to 24 doctors).
Payment categories include: Food & Beverage ($10,799), Consulting ($430,689), Research ($48.2M), Travel & Lodging ($385,982), Royalties ($1.0M).
Astellas Pharma Inc is associated with 2 products in the CMS Open Payments database.